Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager — Live Feedhttps://www.live-feeds.com/feed/novartis-pens-7-8b-deal-for-abogen-s-in-vivo-autoimmune-t-cell-engagerContinuously updated, source-cited coverage. Novartis licenses Abogen mRNA therapy in deal worth up to $7.8 billionhttps://www.live-feeds.com/feed/novartis-pens-7-8b-deal-for-abogen-s-in-vivo-autoimmune-t-cell-engagerhttps://www.live-feeds.com/feed/novartis-pens-7-8b-deal-for-abogen-s-in-vivo-autoimmune-t-cell-engager#u104950Tue, 06 Oct 2026 02:56:22 +0000Novartis has entered a licensing and option agreement with Chinese biotech Abogen Biosciences for an mRNA-encoded T cell engager. The deal is valued at up to $7.8 billion, with Novartis paying $575 million upfront for global rights to the experimental autoimmune treatment. The therapy uses an in vivo approach to produce a CD3xCD19 T cell engager inside the body, which Abogen claims may lower the risk of dangerous cytokine release. The agreement also includes options for other potential RNA programs.Why it mattersWestern pharmaceutical firms are increasingly sourcing innovation from China to of